Trifluridin/tipiracil in treatment of refractory metastatic colorectal cancer - early clinical experience
نویسندگان
چکیده
منابع مشابه
Bevacizumab in the therapy for refractory metastatic colorectal cancer
Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the co...
متن کاملCapecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
3657 Background: The survival of patients (pts) with metastatic colorectal cancer (CRC) has increased recently with the introduction of newer agents. Yet, there remains a need for more effective second- and third-line therapy. We conducted a phase II study to examine an oral combination regimen, capecitabine and thalidomide (Cape/Thal), in patients with previously treated, refractory metastatic...
متن کاملRandomized trial of TAS-102 for refractory metastatic colorectal cancer.
BACKGROUND Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS In this double-blind study, we randomly ass...
متن کاملBiomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.
A novel combination of bevacizumab and everolimus was evaluated in refractory colorectal cancer patients in a phase II trial. In this retrospective analysis, plasma samples from 49 patients were tested for over 40 biomarkers at baseline and after one or two cycles of drug administration. Analyte levels at baseline and change on-treatment were correlated with progression-free survival (PFS) and ...
متن کاملMultimodal treatment of metastatic colorectal cancer.
BACKGROUND Metastases to the liver is the leading cause of death in patients with colorectal cancer. METHODS The authors review the data on diagnosis and management of this clinical problem, and they discuss management options that can be considered. RESULTS Complete surgical resection of metastases from colorectal cancer that are localized to the liver results in 5-year survival rates rang...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologie
سال: 2017
ISSN: 1802-4475,1803-5345
DOI: 10.36290/xon.2017.018